{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:35:58Z","timestamp":1793090158213,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105577","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:30:37Z","timestamp":1788305437000},"page":"105577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["TIL therapy in relapsed\/refractory neuroblastoma: A translational roadmap from immunobiology to early-phase trials"],"prefix":"10.1016","volume":"227","author":[{"given":"Rashin","family":"Mohseni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Kalantari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Behfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Karimizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Khalilzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atoosa","family":"Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-079X","authenticated-orcid":false,"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2026.105577_bib1","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib2","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1038\/s41598-025-89884-3","article-title":"PHD-2\/HIF-1\u03b1 axis mediates doxorubicin-induced angiogenesis in SH-SY5Y neuroblastoma microenvironment: a potential survival mechanism","volume":"15","author":"Abou-Shanab","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105577_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarr\u00e1n","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105577_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jcyt.2024.12.010","article-title":"Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation","volume":"27","author":"Amaria","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105577_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell therapy: promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105577_bib6","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00262-023-03500-9","article-title":"Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection","volume":"72","author":"Balzeau","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105577_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coi.2020.03.004","article-title":"Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy","volume":"64","author":"Barrett","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2015.02.027","article-title":"TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells","volume":"361","author":"Boes","year":"2015","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105577_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41417-023-00599-x","article-title":"\u03b23-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN-\u03b3-dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma","volume":"30","author":"Bruno","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105577_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1394003","article-title":"Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy","volume":"15","author":"Bulashevska","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s12885-019-5693-2","article-title":"Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma","volume":"19","author":"Burgos-Panadero","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib12","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23618","article-title":"The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes","volume":"2","author":"Carlson","year":"2013","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib13","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202503249","article-title":"\u03b3\u03b4 T cells are the prime antitumoral T cells in pediatric neuroblastoma","volume":"8","author":"Castenmiller","year":"2025","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.critrevonc.2026.105577_bib14","unstructured":"Center, M.C., 2023. Tumor Infiltrating Lymphocytes in Pediatric Malignant Solid Tumors: A Prospective Biobanking Study and Phase I Clinical Trial. https:\/\/clinicaltrials.gov\/study\/NCT06047977. (Accessed March 13, 2026."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13073-017-0468-3","article-title":"The neoepitope landscape in pediatric cancers","volume":"9","author":"Chang","year":"2017","journal-title":"Genome Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27229","article-title":"Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma","volume":"65","author":"Chen","year":"2018","journal-title":"Pediatr. blood & Cancer"},{"key":"10.1016\/j.critrevonc.2026.105577_bib17","article-title":"Pediatric oncology drug development and dosage optimization","volume":"13","author":"Cheung","year":"2023","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105577_bib18","article-title":"Direct Targeting of CXCR2 Receptor Inhibits Neuroblastoma Growth: An In Vitro Assessment","volume":"18","author":"Chilamakuri","year":"2025","journal-title":"Pharm. (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aec2632","article-title":"IL-7\/IL-15\/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells","volume":"12","author":"Cole","year":"2026","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib20","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1016\/S1470-2045(25)00434-6","article-title":"Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering","volume":"26","author":"Crowther","year":"2025","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41416-021-01680-8","article-title":"Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance","volume":"126","author":"Darvishi","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105577_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15031101","article-title":"Neuroblastoma in Childhood: Biological Insights, Risk Stratification, and Advances in Multimodal Therapy","volume":"15","author":"De Bona","year":"2026","journal-title":"J. Clin. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105577_bib24","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105577_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"van den Berg","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105577_bib26","article-title":"In-depth analysis of the safety of CAR-T cell therapy for solid tumors","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cells15050441","article-title":"Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies","volume":"15","author":"Du","year":"2026","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib28","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell. Rep. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s002620050267","article-title":"Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma","volume":"42","author":"Facchetti","year":"1996","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105577_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102515","article-title":"Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform","volume":"20","author":"Fang","year":"2025","journal-title":"Stem Cell. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-026-04384-1","article-title":"Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations","volume":"75","author":"Fatahichegeni","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1025194","article-title":"Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14. 18\/CHO antibody with V\u03b39V\u03b42+ \u03b3\u03b4T cells","volume":"5","author":"Fisher","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105577_bib33","unstructured":"Florida, Uo, 2021. PEACH TRIAL: Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma. https:\/\/clinicaltrials.gov\/study\/NCT04837547. (Accessed March 13, 2026."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105577_bib34","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/cancers13071743","article-title":"Combined effects of myeloid cells in the neuroblastoma tumor microenvironment","volume":"13","author":"Frosch","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/0008-5472.CAN-18-2139","article-title":"Macrophage-derived IL1\u03b2 and TNF\u03b1 regulate arginine metabolism in neuroblastoma","volume":"79","author":"Fultang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105577_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2024.104898","article-title":"Natural killer cell-based therapies in neuroblastoma","volume":"407","author":"Ghasempour","year":"2025","journal-title":"Cell. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib37","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.ymthe.2025.05.025","article-title":"Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells","volume":"33","author":"Giudice","year":"2025","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14712598.2022.2064711","article-title":"Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions","volume":"22","author":"Granh\u00f8j","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.105","article-title":"CD276 as a novel CAR NK-92 therapeutic target for neuroblastoma","volume":"4","author":"Grote","year":"2021","journal-title":"Adv. CELL GENE Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_431608","article-title":"Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies","volume":"44","author":"Haanen","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.critrevonc.2026.105577_bib41","article-title":"Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies","volume":"45","author":"Habibi","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s40001-025-03764-0","article-title":"The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis","volume":"31","author":"Habibi","year":"2026","journal-title":"Eur. J. Med. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105577_bib43","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105577_bib44","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fimmu.2019.02816","volume":"10","author":"Heinze","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105577_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105577_bib46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jnci\/djy157","article-title":"Clinical Impact of Tumor Mutational Burden in Neuroblastoma","volume":"111","author":"Hwang","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105577_bib47","unstructured":"Institute, R.P.C., 2016. A Phase I\/IIa Study of TGF\u00df Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies."},{"key":"10.1016\/j.critrevonc.2026.105577_bib48","unstructured":"Iovance Biotherapeutics, I., 2024. A Phase 1, Multicenter, Open-label, 2-stage, Single-arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants With Relapsed or Refractory Solid Tumors. https:\/\/clinicaltrials.gov\/study\/NCT06566092. (Accessed March 13, 2026."},{"key":"10.1016\/j.critrevonc.2026.105577_bib49","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2025.1680410","article-title":"Multiplex engineering and multifunction T cells for precise and effective immunotherapies","volume":"16","author":"Jafarzadeh","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/1878-0261.13404","article-title":"Epigenetic therapies for neuroblastoma: immunogenicity awakens","volume":"17","author":"Jim\u00e9nez","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105577_bib51","article-title":"Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential","volume":"10","author":"Jim\u00e9nez-Reinoso","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0008-8749(03)00079-0","article-title":"Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule","volume":"222","author":"Johnson","year":"2003","journal-title":"Cell. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105577_bib53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/2767-9764.CRC-21-0134","article-title":"Impaired antitumor immune response in MYCN-amplified neuroblastoma is associated with lack of CCL2 Secretion and poor dendritic cell recruitment","volume":"2","author":"Kacher","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jtct.2025.12.009","article-title":"Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients","volume":"32","author":"Karapetyan","year":"2026","journal-title":"Transplant. Cell. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0304-3835(93)90182-9","article-title":"Distinct cytotoxicity against neuroblastoma cells of peripheral blood and tumor-infiltrating lymphocytes from patients with neuroblastoma","volume":"73","author":"Kataoka","year":"1993","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007798","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","volume":"11","author":"Kennedy","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105577_bib57","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase I trial combining decitabine\/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105577_bib58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1349-7006.1995.tb03030.x","article-title":"Interleukin-12 augments the generation of autologous tumor-reactive CD8+ cytotoxic T lymphocytes from tumor-infiltrating lymphocytes","volume":"86","author":"Kuge","year":"1995","journal-title":"Jpn J. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105577_bib59","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel: FDA-approved T-cell therapy for melanoma","volume":"29","author":"Kwong","year":"2024","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105577_bib60","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14. 18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105577_bib61","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s12094-025-03853-w","article-title":"Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse\/progressive disease","volume":"27","author":"de las Heras","year":"2025","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46968-2","article-title":"Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma","volume":"13","author":"Lascano","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105577_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738958","article-title":"Targeting Cbx3\/HP1\u03b3 Induces LEF-1 and IL-21R to Promote Tumor-Infiltrating CD8 T-Cell Persistence","volume":"12","author":"Le","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105577_bib64","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105577_bib65","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3389\/fimmu.2020.01947","article-title":"Re-educating\u201d tumor associated macrophages as a novel immunotherapy strategy for neuroblastoma","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib66","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13046-020-01729-1","article-title":"Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line","volume":"39","author":"L\u00f3pez-Carrasco","year":"2020","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2146860","article-title":"Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-\u03b2\/IL-6 pathway in neuroblastoma","volume":"11","author":"Louault","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib68","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13046-022-02525-9","article-title":"Combined mitoxantrone and anti-TGF\u03b2 treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma","volume":"41","author":"Lucarini","year":"2022","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105577_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1544137","article-title":"T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma","volume":"16","author":"Maggi","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41698-025-01230-y","article-title":"Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma","volume":"10","author":"Mao","year":"2026","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105577_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104648","article-title":"CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology - A comprehensive analysis of clinical trials","volume":"209","author":"Mart\u00ednez-Gamboa","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105577_bib72","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.annonc.2025.04.001","article-title":"Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"36","author":"Mart\u00edn-Lluesma","year":"2025","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012860","article-title":"Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma","volume":"13","author":"Melaiu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105577_bib74","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1158\/1078-0432.CCR-16-2601","article-title":"PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma","volume":"23","author":"Melaiu","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib75","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcyt.2024.08.002","article-title":"Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors","volume":"27","author":"Metts","year":"2025","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1019981","article-title":"Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma","volume":"4","author":"Mina","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70958-7","article-title":"Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed\/refractory neuroblastomas post autologous hematopoietic stem cell transplantation","volume":"14","author":"Mohseni","year":"2024","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib79","article-title":"Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma","volume":"6","author":"Monberg","year":"2025","journal-title":"Cell. Rep. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105577_bib80","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105577_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102964","article-title":"Global, regional, and national epidemiology of childhood neuroblastoma (1990\u20132021): a statistical analysis of incidence, mortality, and DALYs","volume":"79","author":"Nong","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib82","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/2326-6066.CIR-24-0975","article-title":"GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15\/IL21 Exhibit Enhanced Activity against Neuroblastoma","volume":"13","author":"Okada","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105577_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216373","article-title":"Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function","volume":"14","author":"Olle Hurtado","year":"2019","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105577_bib84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-017-2701-1","article-title":"Hypoxia and hypoxia-inducible factors in neuroblastoma","volume":"372","author":"P\u00e5hlman","year":"2018","journal-title":"Cell. Tissue Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105577_bib86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1196\/annals.1322.008","article-title":"Immunogenicity of human neuroblastoma","volume":"1028","author":"Prigione","year":"2004","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30901","article-title":"CD20(high)CD138(low) tumor-infiltrating lymphocytes predominantly related to cytokine-cytokine receptor interactions are associated with favorable outcomes in neuroblastoma patients","volume":"10","author":"Qin","year":"2024","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib88","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12098-018-2834-6","article-title":"Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India","volume":"86","author":"Radhakrishnan","year":"2019","journal-title":"Indian. J. Pediatr."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105577_bib89","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s10555-024-10212-8","article-title":"Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives","volume":"43","author":"Rados","year":"2024","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105577_bib90","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1158\/1078-0432.CCR-09-0829","article-title":"Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo","volume":"15","author":"Reid","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105577_bib91","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01741792","article-title":"Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype","volume":"34","author":"Rivoltini","year":"1992","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105577_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17081303","article-title":"Tertiary Lymphoid Structures Are Associated with Progression-Free Survival of Peripheral Neuroblastic Tumor Patients","volume":"17","author":"Rothe","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib93","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/1078-0432.CCR-12-2528","article-title":"Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells","volume":"19","author":"Santilli","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105577_bib94","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdi226","article-title":"Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients","volume":"16","author":"Schwinger","year":"2005","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001335","article-title":"Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma","volume":"9","author":"Seier","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib96","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","article-title":"B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met\/AKT\/mTOR\/IRF-1 axis in neuroblastoma","volume":"41","author":"Sha","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105577_bib97","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3390\/cancers16081590","article-title":"Unsaturated fatty acid synthesis is associated with worse survival and is differentially regulated by MYCN and tumor suppressor microRNAs in neuroblastoma","volume":"16","author":"Sheeter","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib98","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1838140","article-title":"Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma","volume":"10","author":"Shirinbak","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105577_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119020","article-title":"Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations","volume":"196","author":"Shokouhfar","year":"2026","journal-title":"Biomed. & Pharmacother."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105577_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18071079","article-title":"Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective Treatment","volume":"18","author":"Shubina","year":"2026","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105577_bib101","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1343775","article-title":"PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD(2) antibody ch14.18\/CHO","volume":"6","author":"Siebert","year":"2017","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105577_bib102","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ijc.26498","article-title":"Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments","volume":"131","author":"Soldati","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"1_Supplement","key":"10.1016\/j.critrevonc.2026.105577_bib103","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.4049\/jimmunol.178.Supp.49.9","article-title":"The role of paracrine IL-6 and IL-10 in neuroblastoma progression (49.9)","volume":"178","author":"Song","year":"2007","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib104","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.trecan.2018.09.006","article-title":"NF\u03baB and MHC-1 Interplay in Neuroblastoma and Immunotherapy","volume":"4","author":"Spel","year":"2018","journal-title":"Trends Cancer"},{"issue":"571","key":"10.1016\/j.critrevonc.2026.105577_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2\u2013chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib106","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/jpm11090923","article-title":"\u03b1\u03b2-T cells engineered to express \u03b3\u03b4-T cell receptors can kill neuroblastoma organoids independent of MHC-I expression","volume":"11","author":"Strijker","year":"2021","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12967-022-03238-5","article-title":"Point-of-care cell therapy manufacturing; it\u2019s not for everyone","volume":"20","author":"Stroncek","year":"2022","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105577_bib108","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/bjc.2016.210","article-title":"Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort","volume":"115","author":"Tadeo","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26449","article-title":"A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors","volume":"64","author":"Tadeo","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13046-024-03180-y","article-title":"Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma","volume":"43","author":"Tempora","year":"2024","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105577_bib111","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-24-1690","article-title":"At the Interface of Tumor-Associated Macrophages and Fibroblasts: Immune-Suppressive Networks and Emerging Exploitable Targets","volume":"30","author":"Timperi","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib112","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105577_bib113","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10555-024-10214-6","article-title":"CAR T-cells for pediatric solid tumors: where to go from here?","volume":"43","author":"Trautmann","year":"2024","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105577_bib114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/10935266211039200","article-title":"Collagen XI Alpha 1 (COL11A1) expression in the tumor microenvironment drives neuroblastoma dissemination","volume":"25","author":"Truong","year":"2022","journal-title":"Pediatr. Dev. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105577_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94952","article-title":"Gut microbiota modulates adoptive cell therapy via CD8\u03b1 dendritic cells and IL-12","volume":"3","author":"Uribe-Herranz","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105577_bib116","first-page":"362","article-title":"T-cell receptor repertoire in neuroblastoma patients","volume":"56","author":"Valteau","year":"1996","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105577_bib117","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1158\/2326-6066.CIR-25-0149","article-title":"Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b","volume":"13","author":"Van Pelt","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib118","article-title":"Immune escape mechanisms and future prospects for immunotherapy in neuroblastoma","volume":"2018","author":"Vanichapol","year":"2018","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.critrevonc.2026.105577_bib119","article-title":"Autologous Stem Cell Transplantation for High-Risk Neuroblastoma - A Real-World Evidence from A Tertiary Cancer Care Center in Southern India","author":"Venkatakrishnan","year":"2025","journal-title":"Indian. J. Hematol. Blood Transfus."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105577_bib120","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.annonc.2022.03.011","article-title":"Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities","volume":"33","author":"Venkataramany","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib121","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","volume":"18","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105577_bib122","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1483254","article-title":"Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system","volume":"15","author":"V\u00f6lzke","year":"2024","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105577_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194722","article-title":"Neuroblastoma in the Era of Precision Medicine: A Clinical Review","volume":"15","author":"Wahba","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib124","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcyt.2024.03.011","article-title":"Interfacing data science with cell therapy manufacturing: where we are and where we need to be","volume":"26","author":"Wang","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105577_bib125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2019.04.006","article-title":"Diminished cytolytic activity of \u03b3\u03b4 T cells with reduced DNAM-1 expression in neuroblastoma patients","volume":"203","author":"Wang","year":"2019","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105577_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104995","article-title":"Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma","volume":"25","author":"Webb","year":"2022","journal-title":"iScience"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105577_bib127","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1158\/1078-0432.CCR-18-0599","article-title":"Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma","volume":"24","author":"Wei","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105577_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1187289","article-title":"Breaking down the tumor immune infiltration within pediatric sarcomas","volume":"14","author":"Weil","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2026.105577_bib129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2020.11.014","article-title":"The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology","volume":"144","author":"Wienke","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105577_bib130","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/bloodadvances.2023009729","article-title":"Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease","volume":"7","author":"Wobma","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105577_bib131","article-title":"Deciphering the MYCN-driven metabolic microenvironment of neuroblastoma","author":"Wolf","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib132","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2567.2004.01853.x","article-title":"Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo","volume":"112","author":"Yan","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105577_bib133","first-page":"2024","article-title":"Tertiary lymphoid structures: new immunotherapy biomarker","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105577_bib134","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.62347\/IDXM4018","article-title":"A prognostic metabolism-related gene signature associated with the tumor immune microenvironment in neuroblastoma","volume":"14","author":"Yu","year":"2024","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105577_bib136","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imm.70094","article-title":"Barriers and Strategies to Enhance CAR-T Cell Infiltration in Solid Tumours: A Systematic Review","volume":"178","author":"Zhang","year":"2026","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105577_bib137","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.4049\/jimmunol.181.3.1877","article-title":"Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo","volume":"181","author":"Zhou","year":"2008","journal-title":"J. Immunol."},{"issue":"4, ement 1","key":"10.1016\/j.critrevonc.2026.105577_bib138","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.jamcollsurg.2019.08.472","article-title":"Role of C-C Motif Chemokine Ligand 2 in Metastatic Neuroblastoma","volume":"229","author":"Zobel","year":"2019","journal-title":"J. Am. Coll. Surg."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:47:36Z","timestamp":1793087256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":138,"alternative-id":["S1040842826004646"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105577","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIL therapy in relapsed\/refractory neuroblastoma: A translational roadmap from immunobiology to early-phase trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105577"}}